HALOZYME THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
HALOZYME THERAPEUTICS, INC. (HALO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 3.97% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2026-08-06
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2026-06-30 was 3.97%, a 4.20% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2026-03-31 was 3.62%, a 16.59% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2025-09-30 was 3.74%, a 2.47% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2025-06-30 was 3.81%, a 17.89% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2025 was 3.67%, a 0.55% increase from fiscal 2024.
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2024 was 3.65%, a 8.31% increase from fiscal 2023.
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2023 was 3.37%, a 145.99% increase from fiscal 2022.
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2022 was 1.37%, a 280.56% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | 3.97% 10-Q · filed 2026-08-06 | 3.62% 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | 3.62% 10-Q · filed 2026-05-11 | |||||
| 2025-12-31 | 3.67% 10-K · filed 2026-02-17 | |||||
| 2025-09-30 | 3.74% 10-Q · filed 2025-11-03 | 3.74% 10-Q · filed 2025-11-03 | ||||
| 2025-06-30 | 3.81% 10-Q · filed 2026-08-06 | 3.81% 10-Q · filed 2026-08-06 | ||||
| 2025-03-31 | 4.34% 10-Q · filed 2026-05-11 | |||||
| 2024-12-31 | 3.65% 10-K · filed 2026-02-17 | |||||
| 2024-09-30 | 3.65% 10-Q · filed 2025-11-03 | 3.65% 10-Q · filed 2025-11-03 | ||||
| 2024-06-30 | 4.64% 10-Q · filed 2025-08-05 | 3.80% 10-Q · filed 2025-08-05 | ||||
| 2024-03-31 | 3.80% 10-Q · filed 2025-05-06 | |||||
| 2023-12-31 | 3.37% 10-K · filed 2026-02-17 | |||||
| 2023-09-30 | 4.19% 10-Q · filed 2024-10-31 | 3.37% 10-Q · filed 2024-10-31 | ||||
| 2023-06-30 | 3.37% 10-Q · filed 2024-08-06 | 3.37% 10-Q · filed 2024-08-06 | ||||
| 2023-03-31 | 3.48% 10-Q · filed 2024-05-07 | |||||
| 2022-12-31 | 1.37% 10-K · filed 2025-02-18 | |||||
| 2022-09-30 | 2.66% 10-Q · filed 2023-11-06 | 1.37% 10-Q · filed 2023-11-06 | ||||
| 2022-06-30 | 2.56% 10-Q · filed 2023-08-08 | 1.37% 10-Q · filed 2023-08-08 | ||||
| 2022-03-31 | 1.37% 10-Q · filed 2023-05-09 | |||||
| 2021-12-31 | 0.36% 10-K · filed 2024-02-20 | |||||
| 2021-09-30 | 0.66% 10-Q · filed 2022-11-08 | 0.36% 10-Q · filed 2022-11-08 | ||||
| 2021-06-30 | 0.81% 10-Q · filed 2022-08-09 | 0.36% 10-Q · filed 2022-08-09 | ||||
| 2021-03-31 | 0.36% 10-Q · filed 2022-05-10 | |||||
| 2020-12-31 | 0.22% 10-K · filed 2023-02-21 | |||||
| 2020-09-30 | 0.22% 10-Q · filed 2021-11-02 | 0.22% 10-Q · filed 2021-11-02 | ||||
| 2020-06-30 | 0.31% 10-Q · filed 2021-08-09 | 0.31% 10-Q · filed 2021-08-09 | ||||
| 2020-03-31 | 0.88% 10-Q · filed 2021-05-10 | |||||
| 2019-12-31 | 1.35% 10-K · filed 2022-02-22 | 1.32% 10-K · filed 2020-02-24 | ||||
| 2019-09-30 | 1.35% 10-Q · filed 2020-11-02 | 1.35% 10-Q · filed 2020-11-02 | ||||
| 2019-06-30 | 1.83% 10-Q · filed 2020-08-10 | 1.83% 10-Q · filed 2020-08-10 | ||||
| 2019-03-31 | 2.49% 10-Q · filed 2020-05-11 | |||||
| 2018-12-31 | 2.25% 10-K · filed 2021-02-23 | |||||
| 2018-09-30 | 2.75% 10-Q · filed 2019-11-12 | 2.25% 10-Q · filed 2019-11-12 | ||||
| 2018-06-30 | 2.55% 10-Q · filed 2019-08-06 | 2.25% 10-Q · filed 2018-08-07 | 2.25% 10-Q · filed 2019-08-06 | |||
| 2018-03-31 | 2.25% 10-Q · filed 2019-05-07 | |||||
| 2017-12-31 | 1.73% 10-K · filed 2020-02-24 | |||||
| 2017-09-30 | 1.73% 10-Q · filed 2018-11-06 | 1.73% 10-Q · filed 2018-11-06 | ||||
| 2017-06-30 | 1.92% 10-Q · filed 2018-08-07 | 1.76% 10-Q · filed 2017-08-08 | 1.76% 10-Q · filed 2017-08-08 | |||
| 2017-03-31 | 1.92% 10-Q · filed 2018-05-10 | |||||
| 2016-12-31 | 1.00% 10-K · filed 2019-02-21 | |||||
| 2016-09-30 | 1.00% 10-Q · filed 2017-11-07 | 1.00% 10-Q · filed 2017-11-07 | ||||
| 2016-06-30 | 1.24% 10-Q · filed 2017-08-08 | 1.24% 10-Q · filed 2017-08-08 | ||||
| 2016-03-31 | 1.27% 10-Q · filed 2017-05-09 | |||||
| 2015-12-31 | 1.34% 10-K · filed 2018-02-20 | |||||
| 2015-09-30 | 1.69% 10-Q · filed 2016-11-07 | 1.34% 10-Q · filed 2016-11-07 | ||||
| 2015-06-30 | 1.49% 10-Q · filed 2016-08-09 | 1.34% 10-Q · filed 2016-08-09 | ||||
| 2015-03-31 | 1.34% 10-Q · filed 2016-05-09 | |||||
| 2014-12-31 | 1.73% 10-K · filed 2017-02-28 | |||||
| 2013-12-31 | 0.86% 10-K · filed 2016-02-29 | |||||
| 2012-12-31 | 0.80% 10-K · filed 2015-03-02 | |||||
| 2011-12-31 | 1.14% 10-K · filed 2014-02-28 | |||||
| 2010-12-31 | 1.39% 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |